About Colchicine

FDA-Approved Colchicine for Gout Flare Prevention in Adults

Colchicine comes from a plant called Colchicum autumnale, or autumn crocus, which is a member of the lily family.1 Plant extracts containing colchicine have been used to prevent gout flares for more than 2,000 years.1 West-Ward Pharmaceuticals (now known as Hikma Pharmaceuticals USA Inc.) received FDA approval for Mitigare® (Colchicine) 0.6 mg Capsules in 2014.

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis has not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

 

History of Mitigare®

2006 
The U.S. Food and Drug Administration (FDA) announced a new initiative to promote testing of medicines in use prior to the agency’s existence. Despite the fact that colchicine had been used to prevent gout flares for hundreds of years, unapproved formulations of the drug were banned a few years later.

2009 
The FDA approved Colcrys® (colchicine, USP) 0.6 mg tablet, which launched at a significantly higher price than pre-existing unapproved colchicine generics.

2010
Colcrys® gained exclusivity in 2010 and began raising the price on Colchicine. Patients were forced to pay a premium price for Colcrys®, the only FDA-approved colchicine product at that time.

2014
The FDA approved Mitigare® (Colchicine) 0.6 mg Capsules, the first and only other branded colchicine product for prevention of gout flares in adults.

2015 
Mitigare® and Authorized Generic Colchicine Capsules launch, generating competition and creating a possibility for people with gout to save on colchicine treatment for prevention of gout flares.

2019 
Hikma Pharmaceuticals USA Inc. launches Colchicine.com to offer information about Authorized Generic Colchicine Capsules.

2020 and beyond 
Hikma Pharmaceuticals USA Inc. continues to provide Mitigare® and Authorized Generic Colchicine Capsules as affordable options to help adults prevent gout flares.

Commitment to Affordable Gout Flare Prevention

West-Ward Pharmaceuticals brought Mitigare® to market to offer patients an affordable treatment option for gout flare prevention.

  • Hikma continues to offer lower-priced brand name and Generic Colchicine Capsules for adult gout flare prevention.2
  • Visit Colchicine.com to learn more about Authorized Generic Colchicine Capsules as an affordable option for gout flare prevention.
All registered trademarks are the property of their respective owners.
At Migitare.com you can sign up for Mitigare® home delivery and find gout flare prevention, diet and lifestyle tips in our Gout Flare Prevention blog.

Take Control With Information

Get the latest information on gout news, patient stories, diet and lifestyle tips and much more.

GOUT BLOG

References

  1. Dubchak N, Falasca G. New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis. 2010;3:145-166.
  2. First Databank. AnalySource® website. Available at: https://www.analysource.com/. Accessed January 6, 2020.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.